MedMira Increases Market Traction with Approval and Sales for Multiplo Triple Test in Moldova and Ukraine

Halifax, Nova Scotia, October 7, 2008 – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostics and rapid flow-through technology, announced today that it has made an initial shipment of its Multiplo HBV/HIV/HCV Rapid Tests (Multiplo HBV/HIV/HCV) to its regional distribution partner in Romania, S.C. Roned International S.R.L. They have received approval to sell Multiplo HBV/HIV/HCV in Moldova and Ukraine and will immediately begin selling to public health programs and participating in NGO tender opportunities.

“We are excited to build upon the success we have had with MedMira rapid tests in Romania. The Multiplo test is a perfect product for the market here in Romania, Moldova, and Ukraine, where HIV/Hepatitis co-infections are on the rise,” said Dumitru Vescu, Executive Director of S.C. Roned International S.R.L. and President of the Romania-Moldova Chamber of Commerce and Industry. “We have had a great response with the initial introduction of this product and will now move to a wider distribution of these tests to our customers. MedMira has been an excellent partner and we look forward to adding new MedMira rapid tests to our line of products in the future.”

Multiplo HBV/HIV/HCV is one of MedMira’s multiple rapid diagnostic tests which simultaneously detect antibodies to HIV and the hepatitis B and C viruses in a single drop of blood. Multiplo stands alone as the only commercially available rapid test for HIV and Hepatitis co-infection. Multiplo was launched earlier this year in the United Nations Office on Drugs and Crime (UNODC) Behavioural Surveillance Surveys (BSS) Among Injecting Drug Users and Sex Workers in Romania.

“We are seeing exciting growth opportunities in Eastern Europe for MedMira’s products as governments and healthcare systems continue to integrate rapid tests for HIV and Hepatitis in to prevention and control programs,” said Hermes Chan, president and CEO, MedMira Inc. “Dumitru and his team know this market well and they are continually seeking new opportunities to expand the distribution and sales of our rapid tests in South Eastern Europe.”

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

-30-

Contacts:

Dr. James Smith, Investor Relations & Corporate Affairs

Tel: 902-450-1588

Email: ir@medmira.com

Andrea Young, Corporate Communications

Tel. 902-450-1588

Email: media@medmira.com